Safety communication
FDA safety communication: GLP-1 medications and gastroparesis
Ozempic, Wegovy, Mounjaro, Zepbound · Announced 2024-05-14 · Last reviewed May 2026
Reviewed by the glpzoom Editorial Team against primary clinical sources — FDA labeling, peer-reviewed trials, and specialty-society guidelines.
Content current as of May 2026; updated when guidance or availability changes.
The FDA acknowledged a pattern of MedWatch reports describing gastroparesis (severely delayed gastric emptying) in GLP-1 users, including persistence of symptoms after drug discontinuation in some cases. The communication did not establish causation but advised prescribers to screen for baseline gastric-emptying issues and to discontinue GLP-1 medications in patients developing persistent severe upper GI symptoms. Prescribing labels were updated to include gastroparesis in the Warnings and Precautions section across the Wegovy, Ozempic, Zepbound, and Mounjaro labels.
What's affected
- All GLP-1 receptor agonists: Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Rybelsus
- Label updates pushed through 2024-2025 for all affected products
What patients should do
- Disclose any history of gastroparesis or chronic upper GI symptoms to your prescriber before starting GLP-1s
- Report persistent nausea, vomiting, or early satiety lasting beyond first 4-6 weeks of treatment
- Symptoms which persist after discontinuation should trigger gastroenterology consultation